Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch from protease inhibitor or efavirenz to raltegravir for liver fat and metabolic outcomes in overweight adults with HIV
2017-003430-85Phase 4Completed
- Sponsor
- Helsinki University Hospital
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of raltegravir and efavirenz in human immunodeficiency virus infection (HIV), metabolic dysfunction-associated steatotic liver disease (MASLD) and cardiometabolic risk (CMR) (2 arms), sponsored by Helsinki University Hospital. Primary endpoint: Change in liver fat content. Started Sep 2017; status: completed.
02
Drugs
raltegravirefavirenz
03
Conditions
human immunodeficiency virus infection (HIV)metabolic dysfunction-associated steatotic liver disease (MASLD)cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2017-003430-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003430-85.